
Smardii
OperatingSmardii, Inc.
Software & AI · Miami, DE · Founded 2016
A New Standard of Care for Elderlies
Financials
FY2019–FY2022 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Fundraising history
Team
9 peopleAlpesh is a successful serial-entrepreneur who was one of the early investors in Smardii. He immediately believed in Smardii’s potential as a much-needed disruptive technology. His experience, as the owner of many successful businesses across the United States, makes him a valuable asset to the company and its Board of Directors.

Edward is Smardii's principal engineer responsible for product development and go-to market activities, such as contract manufacturing and regulatory matters. He has over 20 years of experience as a principal engineer at a Fortune 500 medical technology company.

MIT and Princeton Engineering graduate, Greg was a general manager at Baxter Labs, responsible for a medical device division. After Baxter, he has spent over 25 years in the life sciences industry. He has served on ~20 boards of directors, several corporate advisory boards and the Columbia University Department of Ophthalmology Board of Advisors. During his career, he has been involved in 7 IPOs and 5 mergers.

John is responsible for Smardii's marketing, sales, and customer engagement activities. He has over 30 years of experience in healthcare and medical products, previously at Dale and Johnson & Johnson, just to name a few. He has a perfect knowledge of the healthcare industry, its various business channels, and helps growing the Smardii brand through customer engagement and strategic partnerships.

Mathieu has over 20 years of experience as a Medical Doctor and PhD in France. He graduated France’s premier medicine school (Marseille) with Magna Cum Laude in 2004, where he did his residency between 2000 and 2004, notably in the geriatric and ER pediatric units. He is a Micronutrient / Morphological Medicine and Anti-Age specialist (MMAA) and is a Medical Expert Witness before the French courts. He is a practicing doctor at many Skilled Nursing Facilities in France, hence has a strong knowledge of medical issues elderlies are experiencing, and operational challenges healthcare operators are facing. As a practitioner, Mathieu was instrumental in Smardii’s shift from the original baby-oriented solution to what it has become today, i.e. an adult-focused remote patient monitoring tool.

Mrugesh has over 14 years of experience as a Senior Communications Engineer. He has a bachelor’s and master’s degrees in Computer Engineering from Stevens Institute of Technology with a concentration on communications and networks. He's proficient in script programming as well as hardware prototyping.

Sebastien has over 18 years of experience in the corporate world, acting as a Corporate M&A attorney, admitted to practice law in New York and Paris, and previously practicing in Luxembourg. During his career, he advised Private Equity and Fortune 500 Multinational Companies on their legal, accounting, tax structuring, international operations, debt/equity financing, mergers & acquisitions, and public listing needs. Through previous employment (some of the world’s largest corporate administration firms) he acted as board director of many Luxembourg vehicles for the account of large U.S. multinational companies and Private Equity firms. He helped clients set up structures, expand operations (in over 70 countries), and go through corporate transactions and public listings. He is an expert in corporate carve-outs, international expansion, growth strategies and implementation for a wide array of clients (from startups to MNCs). He participated in 2 successful IPOs, one for a well-known global manufacturer, the other for a leading data analytics company. He brings his corporate governance expertise to the board of directors, and to the company’s leadership.

Spiro is a business strategist and tax advisor with a long track record and expertise in life sciences. During his career, he acted as subject matter expert for some of the world's largest tax and accounting advisory firms. He is responsible for Smardii's financial activities, which includes all accounting, reporting, and tax-related matters.

Vikram has over 20 years of experience with institutional clients on Wall Street including leading deep due diligence for large Private Equity/Hedge Funds, securing procurement from large pension funds, product development, client operations and onboarding, marketing operations, strategy, execution, vendor due diligence, selection and management, operational due diligence, systems onboarding, building and managing marketing and client relation teams, and fund raising. Throughout his career he has helped launch over 20 products totaling over $15 billion in AuM. He has also served on ESG Committees and has led various initiatives on responsible investing. He has an in-depth knowledge of the sell-side due diligence process and has a strong track record of building brand value and raising awareness.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 5 annual reports (FY2021–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form C-TRJun 27, 20240001862802-24-000003EDGAR
- Form C-ARJun 14, 20230001665160-23-001383EDGAR
- Form C-UOct 5, 20220001665160-22-002619EDGAR
- Form C-ARApr 28, 20220001665160-22-001086EDGAR
- Form C-UDec 9, 20210001665160-21-002164EDGAR
- Form C/ANov 15, 20210001665160-21-002023EDGAR
- Form C/AAug 27, 20210001665160-21-001537EDGAR
- Form CAug 5, 20210001665160-21-001410EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.